TSE:4521Pharmaceuticals
Kaken Pharmaceutical (TSE:4521) Quarterly Profit Contrasts With Loss-Making Trailing Year Narrative
Kaken Pharmaceutical (TSE:4521) has posted its Q3 2026 numbers with revenue of ¥18,261 million and basic EPS of ¥10.72, while trailing twelve month figures show revenue of ¥75,662 million and a basic EPS loss of ¥100.31. The company has reported quarterly revenue ranging from ¥20,489 million in Q2 2026 to ¥18,867 million in Q1 2026, with EPS moving from ¥19.04 in Q2 2026 to ¥7.12 in Q1 2026 and a sharp loss of ¥133.99 in Q4 2025, which together present a mixed picture for earnings quality...